These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1369 related items for PubMed ID: 29748368

  • 1. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.
    Eur J Heart Fail; 2020 Feb 11; 22(2):196-213. PubMed ID: 31816162
    [Abstract] [Full Text] [Related]

  • 10. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep 11; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P, Acharya T.
    Am J Cardiovasc Drugs; 2019 Jun 11; 19(3):249-257. PubMed ID: 30767126
    [Abstract] [Full Text] [Related]

  • 12. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E.
    BMJ; 2024 Jun 26; 385():e078483. PubMed ID: 38925801
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P.
    Diabetologia; 2019 Mar 26; 62(3):357-369. PubMed ID: 30607467
    [Abstract] [Full Text] [Related]

  • 14. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K.
    JAMA; 2018 Apr 17; 319(15):1580-1591. PubMed ID: 29677303
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC, Hettige TS, Cooper ME.
    Adv Chronic Kidney Dis; 2018 Mar 17; 25(2):149-157. PubMed ID: 29580579
    [Abstract] [Full Text] [Related]

  • 19. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ.
    Postgrad Med; 2013 May 06; 125(3):7-20. PubMed ID: 23748503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.